Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
Eur J Dermatol ; 34(3): 287-293, 2024 Jun 01.
Artigo em Inglês | MEDLINE | ID: mdl-39015962

RESUMO

Palmoplantar keratoderma (PPK) is a group of -disorders with genetic and phenotypic heterogeneity featuring skin thickening of the palms and soles. More than 60 genes involved in various biological processes are implicated in PPK. PIK3CA is an oncogene encoding p110α, and its somatic variants contribute to a spectrum of congenital overgrowth disorders, including epidermal nevi (EN). To identify the genetic basis and elucidate the pathogenesis of a patient with unilateral focal PPK. Whole-exome sequencing and Sanger sequencing combined with laser capture microdissection (LCM) were performed on genomic DNA extracted from the patient's peripheral blood and skin lesion. Skin biopsies were taken from the lesion of the patient and normal controls for immunofluorescence. Molecular docking was performed using Alphafold2-multimer. A three-year-old girl presented with unilateral focal PPK with an identified missense -variant (c.3140A>G, p.His1047Arg) in PIK3CA from affected tissue. This variant only existed in the lesional epidermis. Elevated PI3K/AKT/mTOR signalling in the affected epidermis and an increased number of Ki67-positive keratinocytes were demonstrated. Molecular docking indicated instability of the p110α-p85α dimer caused by the PIK3CA His1047Arg variant. We describe the first PPK case associated with a variant in PIK3CA, which expands the spectrum of PIK3CA-related disorders. Our study further underscores the importance of the PI3K/AKT/mTOR pathway in the homeostasis of skin keratinization.


Assuntos
Classe I de Fosfatidilinositol 3-Quinases , Ceratodermia Palmar e Plantar , Mutação de Sentido Incorreto , Proteínas Proto-Oncogênicas c-akt , Transdução de Sinais , Serina-Treonina Quinases TOR , Humanos , Classe I de Fosfatidilinositol 3-Quinases/genética , Feminino , Serina-Treonina Quinases TOR/genética , Serina-Treonina Quinases TOR/metabolismo , Ceratodermia Palmar e Plantar/genética , Ceratodermia Palmar e Plantar/patologia , Proteínas Proto-Oncogênicas c-akt/genética , Proteínas Proto-Oncogênicas c-akt/metabolismo , Pré-Escolar , Transdução de Sinais/genética , Sequenciamento do Exoma
2.
Curr Cancer Drug Targets ; 23(2): 145-158, 2023.
Artigo em Inglês | MEDLINE | ID: mdl-35975844

RESUMO

AIMS: The study aims to explore new potential treatments for cervical cancer. BACKGROUND: Cervical cancer is the second most common cancer in women, causing >250,000 deaths worldwide. Patients with cervical cancer are mainly treated with platinum compounds, which often cause severe toxic reactions. Furthermore, the long-term use of platinum compounds can reduce the sensitivity of cancer cells to chemotherapy and increase the drug resistance of cervical cancer. Therefore, exploring new treatment options is meaningful for cervical cancer. OBJECTIVE: The present study was to investigate the effect of sildenafil on the growth and epithelial-tomesenchymal transition (EMT) of cervical cancer. METHODS: HeLa and SiHa cells were treated with sildenafil for different durations. Cell viability, clonogenicity, wound healing, and Transwell assays were performed. The levels of transforming growth factor-ß1 (TGF-ß1), transforming growth factor-ß type I receptor (TßRI), phosphorylated (p-) Smad2 and p-Smad3 in cervical cancer samples were measured. TGF-ß1, Smad2 or Smad3 were overexpressed in HeLa cells, and we measured the expression of EMT marker proteins and the changes in cell viability, colony formation, etc. Finally, HeLa cells were used to establish a nude mouse xenograft model with sildenafil treatment. The survival rate of mice and the tumor size were recorded. RESULTS: High concentrations of sildenafil (1.0-2.0 µM) reduced cell viability, the number of HeLa and SiHa colonies, and the invasion/migration ability of HeLa and SiHa cells in a dose- and time-dependent manner. The expression of TGF-ß1, TßRI, p-Smad2 and p-Smad3 was significantly enhanced in cervical cancer samples and cervical cancer cell lines. Sildenafil inhibited the expression of TGF-ß1-induced EMT marker proteins (Snail, vimentin, Twist, E-cadherin and N-cadherin) and p-Smad2/3 in HeLa cells. Overexpression of TGF-ß1, Smad2, and Smad3 reversed the effect of sildenafil on EMT, viability, colony formation, migration, and invasion ability of HeLa cells. In the in vivo study, sildenafil significantly increased mouse survival rates and suppressed xenograft growth. CONCLUSION: Sildenafil inhibits the proliferation, invasion ability, and EMT of human cervical cancer cells by regulating the TGF-ß1/Smad2/3 pathway.


Assuntos
Fator de Crescimento Transformador beta1 , Neoplasias do Colo do Útero , Animais , Camundongos , Humanos , Feminino , Células HeLa , Fator de Crescimento Transformador beta1/farmacologia , Citrato de Sildenafila/farmacologia , Neoplasias do Colo do Útero/tratamento farmacológico , Transdução de Sinais , Transição Epitelial-Mesenquimal , Movimento Celular , Linhagem Celular Tumoral , Proteína Smad2/metabolismo , Proteína Smad2/farmacologia
3.
Transl Cancer Res ; 12(12): 3409-3424, 2023 Dec 31.
Artigo em Inglês | MEDLINE | ID: mdl-38192993

RESUMO

Background: Endometrial cancer (EC) is one of the most common malignancies among women. To improve the prognosis and treatment of EC, finding out a phosphatase and tensin homolog deleted on chromosome 10 (PTEN)-associated prognostic signature would be beneficial. Methods: EC clinical data, genetic mutation data, and transcriptome data were downloaded from The Cancer Genome Atlas (TCGA) database. To clarify the specific PTEN-associated signature, cox regression analyses were performed. The clinical value of the selected signature on the overall survival (OS) and the secretoglobin family 2A member 1 (SCGB2A1)-independent analysis, immune and functional analysis were investigated respectively. Results: Five hundred and fourteen EC samples were screened and PTEN mutation occupied 57%. Enrichment analysis indicated that mutant-type PTEN was enriched for pathways related to the upregulated human T-cell leukemia virus-1 (HTLV-1) infection and estrogen signaling pathway. SCGB2A1 was identified by cox regression analysis. Immune analysis exhibited significant immune infiltration with higher expression of T cells, B cells, and macrophage groups. Immune-checkpoint transcripts CD274 molecule (CD274), and cytotoxic T-lymphocyte associated protein 4 (CTLA4), hepatitis A virus cellular receptor 2 (HAVCR2), lymphocyte activation gene 3 (LAG3), programmed cell death 1 (PDCD1), PDCD1 ligand 2 (PDCD1LG2), T cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibition motif domains (TIGIT), and sialic acid binding immunoglobulin like lectin 15 (SIGLEC15) were discovered statistically different. In addition, the low-SCGB2A1 group had worse OS than the high-SCGB2A1 group. SCGB2A1 showed significant area under the curve (AUC) values in a time-dependent receiver operating characteristic (ROC) analysis. Prevalence of microsatellite instability (MSI) was detected and SCGB2A1 showed a negative correlation with EC. Immune checkpoint blockade (ICB) response indicated a worse immune response in the low-SCGB2A1 group. The distribution of one-class linear regression (OCLR) scores reflected the negative correlation between messenger RNA expression-based stemness index (mRNAsi) and prognostic gene expression. Furthermore, several SCGB2A1-related signaling pathways in EC were identified. Conclusions: SCGB2A1 is a prognostic immunometabolic signature for patients with EC, which may help improve the prognosis and therapeutic effect.

4.
Cell Biol Int ; 46(1): 118-128, 2022 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-34643308

RESUMO

Deletion and mutation of phosphatase and tensin homolog deleted on chromosome10 (PTEN) are closely associated with the occurrence of tumors. Tumor suppressor gene PTEN mutation plays an important role in the pathogenesis of ovarian cancer. However, it has been unclear whether it can regulate the senescence of ovarian cancer cells. We speculated that PTEN might inhibit the occurrence and development of ovarian cancer by promoting the expression of P21. We found that the expression of TRIM39 in human ovarian cancer was significantly diminished. In SKOV3 cells treated with naringin, the expression of TRIM39, which binds P21 and inhibits P21 degradation, was significantly elevated. Real-time polymerase chain reaction (PCR), Western blot, and immunofluorescence were used to detected the expression of PTEN, p21, and TRIM39, ß-galactosidase Staining was used to detect cell senescence, Ki67 staining was used to observe cell proliferation, Trim39 interference or overexpression assay was used to detect its function. We speculated that PTEN might promote SKOV3 cell senescence by increasing TRIM39 expression and decreasing P21 degradation. Furthermore, by interfering with TRIM39 in SKOV3 cells, we found that the expression of P21 was downregulated, and the number of senescent SKOV3 cells decreased. With overexpression of TRIM39 in SKOV3 cells, the expression of P21 was upregulated, and the number of senescent SKOV3 cells increased. When naringin, a PTEN agonist, was added to SKOV3 cells in which TRIM39 protein was interfered with, the expression of P21 was significantly lower than that in the control group, and the number of senescent ovarian cancer cells was significantly diminished. Our results indicated that PTEN maintained the stability of P21 and decreased the degradation of P21 by increasing TRIM39 expression, thus promoting the senescence of SKOV3 cells, and PTEN maintained the stability of p21 and promoted the aging of SKOV3 cells might be a novel therapeutic target for ovarian cancer.


Assuntos
Proliferação de Células , Senescência Celular , Inibidor de Quinase Dependente de Ciclina p21/metabolismo , Neoplasias Ovarianas/enzimologia , PTEN Fosfo-Hidrolase/metabolismo , Linhagem Celular Tumoral , Proliferação de Células/efeitos dos fármacos , Senescência Celular/efeitos dos fármacos , Inibidor de Quinase Dependente de Ciclina p21/genética , Feminino , Flavanonas/farmacologia , Regulação Neoplásica da Expressão Gênica , Humanos , Neoplasias Ovarianas/tratamento farmacológico , Neoplasias Ovarianas/genética , Neoplasias Ovarianas/patologia , PTEN Fosfo-Hidrolase/genética , Proteólise , Transdução de Sinais , Ubiquitina-Proteína Ligases/genética , Ubiquitina-Proteína Ligases/metabolismo
5.
Arch Dermatol Res ; 310(7): 561-566, 2018 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-29931443

RESUMO

Keloids are skin fibroproliferative tumors characterized by locally invasive growth of fibroblasts and excessive collagen deposition. The objective of this study is to investigate the molecular basis of the keloid scar by studying the mutation of related genes. We performed gene screening of mechanoreceptors by quantitative polymerase chain reaction (qPCR), Sanger sequencing to detect the CXCR1gene mutation, and immuno-histochemistry to determine CXCR1 protein expression. Among the genes encoding mechanoreceptors, the expression of CXCR1 mRNA was significantly higher in keloid scar tissues than in the surrounding tissues of normal controls (P < 0.05). Sequencing analysis identified a novel missense mutation, c.574G > A (p.Gly192Glu). Immunohistochemistry showed heightened protein expression of CXCR1 in keloid scars as compared to controls. Our findings indicate that CXCR1 gene mutation and altered protein expression are associated with keloid scar development. Identification of the CXCR1 gene mutation might provide insights into the molecular mechanism underlying keloid scar and underscores the potential importance of mechanoreceptors in keloid scar pathogenesis.


Assuntos
Cicatriz Hipertrófica/genética , Queloide/genética , Mutação de Sentido Incorreto/genética , RNA Mensageiro/genética , Receptores de Interleucina-8A/genética , Pele/patologia , China , Cicatriz Hipertrófica/metabolismo , Feminino , Testes Genéticos , Humanos , Imuno-Histoquímica , Queloide/metabolismo , Masculino , Mecanorreceptores/metabolismo , Receptores de Interleucina-8A/metabolismo , Estudos Retrospectivos , Pele/metabolismo , Regulação para Cima
6.
Int J Clin Exp Med ; 8(11): 21703-6, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-26885130

RESUMO

OBJECTIVE: To assess the remission rate and outcome of pregnancy of patients who had moderate and severe ovarian endometriosis after conservative surgery. We also wished to analyze the associated factors of recurrence. METHODS: Weconducted retrospective analyses of 199 cases with stage II-IV ovarian endometriosis who had preserved fertility under laparoscopic surgical treatment. Postoperatively, the 199 patients were divided into three groups: 43 cases underwent surgical treatment alone (group A); 47 were given a gonadotropin-releasing hormone agonist (GnRH-α) (group B), and 109 were given mifepristone (group C). Ten cases in group A were infertile, 26 cases in group B, and 38 cases in group C. All patients were followed up for 3 years. This study was approved by the Ethics Committee of Yangpu District Central Hospital. RESULTS: In groups A, B and C, the remission rate was 58.13%, 70.21% and 60.55% and the difference not significant (P=0.384); Recurrence rates were 27.90%, 12.76% and 24.77%, and the difference between them significant (P<0.05). The recurrence rate in group B was the lowest. The natural pregnancy rate after surgery in the three study groups (untreated, GnRH-α and mifepristone) was 30%, 34.61% and 28.94% but this difference was not significant. CONCLUSION: Surgery can improve the symptom remission rate and fertility of patients. Postoperative drug therapy does not improve the chance of pregnancy.

7.
J Obstet Gynaecol Res ; 40(9): 2051-7, 2014 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-25181625

RESUMO

AIM: Myosin is involved in cell contraction and motility, but it is unclear whether it is involved in cell proliferation in uterine myoma. In this study therefore we aimed to explore the role of myosin in uterine myoma. MATERIAL AND METHODS: Immunohistochemistry and real-time polymerase chain reaction were used to determine the expression of myosin light chain (MLC), myosin heavy chain (MHC) and myosin light chain kinase (MLCK) in patient uterine myoma and adjacent smooth muscle tissue. Human uterine fibroid cells were isolated and cultured in vitro, myosin heavy chain 11 (MHC subtype expressed in uterine fibroid cells) was knocked down by RNA interference to reduce the expression of myosin, then cell proliferation was determined by the methyl thiazol tetrazolium bromide method. To explore the possible mechanism of reduced cell proliferation after myosin heavy chain 11 knockdown, the downstream proteins collagen I, insulin-like growth factor-1, fibronectin and proteoglycans were analyzed. RESULTS: Expression of MLC, MHC, MLCK and p-MLCK in uterine myoma cells was significantly higher than in adjacent smooth muscle cells. After knockdown of MHC, smooth muscle cell proliferation decreased, and the production of collagen I, insulin-like growth factor-1 and fibronectin was also reduced, but proteoglycans did not show any significant change. CONCLUSION: Myosin is overexpressed in uterine myoma, and the overexpression of myosin is associated with both uterine contraction and tumor development of uterine myoma.


Assuntos
Proteínas de Ligação ao Cálcio/metabolismo , Leiomiomatose/metabolismo , Cadeias Pesadas de Miosina/metabolismo , Cadeias Leves de Miosina/metabolismo , Quinase de Cadeia Leve de Miosina/metabolismo , Regulação para Cima , Neoplasias Uterinas/metabolismo , Útero/metabolismo , Adulto , Proteínas de Ligação ao Cálcio/genética , Proliferação de Células , Células Cultivadas , Ativação Enzimática , Feminino , Humanos , Leiomioma/metabolismo , Leiomioma/patologia , Leiomioma/cirurgia , Leiomiomatose/patologia , Leiomiomatose/cirurgia , Pessoa de Meia-Idade , Cadeias Pesadas de Miosina/antagonistas & inibidores , Cadeias Pesadas de Miosina/genética , Cadeias Leves de Miosina/genética , Quinase de Cadeia Leve de Miosina/genética , Proteínas de Neoplasias/antagonistas & inibidores , Proteínas de Neoplasias/genética , Proteínas de Neoplasias/metabolismo , Fosforilação , Processamento de Proteína Pós-Traducional , Interferência de RNA , Células Tumorais Cultivadas , Neoplasias Uterinas/patologia , Útero/patologia , Útero/cirurgia
8.
Int J Clin Exp Med ; 7(5): 1324-30, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-24995090

RESUMO

AIM: To investigate the expression of calcium channel protein in uterine fibroids, and to explore the relationship between calcium signaling pathway and the pathogenesis of uterine fibroids. METHODS: Uterine fibroid tissues (UFC) and adjacent healthy uterine smooth muscle tissues (SMC) were collected from 30 cases of uterine fibroids. Real-time quantitative PCR and western blot were used to detect cell membrane calcium channel protein subtypes: TRPC1, TRPC3, TRPC4, TRPC6, TRPM6 and TRPM7. The effects of genes exhibiting most-notable differences on cell proliferation were examined using gene interference techniques. RESULTS: We found that calcium channel protein subtypes expressed differently in fibroids and the surrounding smooth muscles. The mRNA and protein expressions of TRPC1 and TRPM7 were higher in uterine fibroid tissues than in smooth muscle (P < 0.05), while no obvious difference was found in terms of other subtypes (TRPC3, TRPC4, TRPC6 and TRPM6). In cultured uterine leiomyoma cells, modifying the expressions of TRPC1 and TRPM7 significantly affected the proliferation rate of uterine fibroids. CONCLUSION: Calcium channel subtypes TRPC1 and TRPM7 exhibit different expression patterns in uterine fibroids and surrounding smooth muscles, suggesting that calcium signaling pathway regulated by these calcium channel proteins may be associated with the incidence of uterine fibroids.

9.
Eur J Obstet Gynecol Reprod Biol ; 168(2): 199-203, 2013 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-23398724

RESUMO

OBJECTIVE: To investigate the expression of cyclooxygenase-2 (COX-2) in uterine fibroids and healthy uterine smooth muscle as well as its role in the pathogenesis of uterine fibroids. METHODS: We collected uterine fibroid tissues and their paired adjacent healthy uterine smooth muscle tissues from 30 cases of uterine fibroids. We used immunohistochemistry and quantitative real-time PCR, as well as western blot to detect COX-2 expression. Using the COX-2 inhibitors NS-398 and celecoxib, we observed the response to the inhibitors in the healthy and fibroid smooth muscle cell pairs. RESULTS: COX-2 was detected by immunohistochemistry in both uterine fibroids and uterine smooth muscle, with higher immunoreactivity in uterine fibroids; the positive index of the smooth muscle cells was 11.90 and the positive index of uterine fibroids cells was 46.50 (P<0.05). The expression of COX-2 mRNA in uterine fibroids was higher (0.122±0.062) than in normal smooth muscle tissue (0.025±0.009; P<0.05). Also, the western blot results showed that COX-2 expression was significantly higher in uterine fibroid cases, as compared to the expression in uterine smooth muscle. Immunofluorescence showed that the occurrence of COX-2 was obviously higher in smooth muscle cells of uterine fibroids than in the healthy smooth muscle cells. NS-398 or celecoxib significantly inhibited the proliferation of smooth muscle cells of uterine fibroids, but did not inhibit the proliferation of healthy smooth muscle cells. Accordingly, NS-398 or celecoxib significantly reduced the expression of the downstream metabolite of COX-2, PGE2, in the smooth muscle cells of uterine fibroids, but not in healthy smooth muscle cells. CONCLUSION: COX-2 expression in uterine fibroids was significantly higher than in healthy uterine smooth muscles. The inhibition of COX-2 activity significantly reduced the proliferation of smooth muscle cells of the uterine fibroids, suggesting that COX-2 plays an important role in the pathogenesis of uterine fibroids.


Assuntos
Ciclo-Oxigenase 2/metabolismo , Indução Enzimática , Leiomioma/metabolismo , Miométrio/metabolismo , Proteínas de Neoplasias/metabolismo , Neoplasias Uterinas/metabolismo , Adulto , Antineoplásicos/farmacologia , Western Blotting , Proliferação de Células/efeitos dos fármacos , Células Cultivadas , Ciclo-Oxigenase 2/química , Ciclo-Oxigenase 2/genética , Inibidores de Ciclo-Oxigenase 2/farmacologia , Dinoprostona/antagonistas & inibidores , Dinoprostona/metabolismo , Feminino , Humanos , Imuno-Histoquímica , Leiomioma/tratamento farmacológico , Leiomioma/patologia , Leiomioma/cirurgia , Pessoa de Meia-Idade , Miométrio/efeitos dos fármacos , Miométrio/patologia , Miométrio/cirurgia , Proteínas de Neoplasias/antagonistas & inibidores , Proteínas de Neoplasias/genética , RNA Mensageiro/metabolismo , Reação em Cadeia da Polimerase em Tempo Real , Células Tumorais Cultivadas , Neoplasias Uterinas/tratamento farmacológico , Neoplasias Uterinas/patologia , Neoplasias Uterinas/cirurgia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA